Go Pro
→ Are you leaving Social Security money on the table? (From Money Pickle) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$3.71
+5.4%		$5.41
$3.40
▼
$12.05
$4.34M1.47401,119 shs174,009 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.02
-25.0%		$0.04
$0.01
▼
$0.13
$809K-0.5328,058 shs379,445 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.28
-3.8%		$2.17
$1.27
▼
$14.64
$4.74M1.821.17 million shs167,747 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.71
-3.8%		$0.69
$0.57
▼
$2.79
$4.51M4.965.49 million shs445,300 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
+5.40%-3.64%-34.80%-42.93%-53.60%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-25.00%-50.00%-60.53%-57.14%-87.78%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-3.76%-18.21%-36.95%-71.17%-90.05%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-3.81%+14.97%+10.02%-30.80%-44.31%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$3.71
+5.4%		$5.41
$3.40
▼
$12.05
$4.34M1.47401,119 shs174,009 shs
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.02
-25.0%		$0.04
$0.01
▼
$0.13
$809K-0.5328,058 shs379,445 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.28
-3.8%		$2.17
$1.27
▼
$14.64
$4.74M1.821.17 million shs167,747 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.71
-3.8%		$0.69
$0.57
▼
$2.79
$4.51M4.965.49 million shs445,300 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
+5.40%-3.64%-34.80%-42.93%-53.60%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-25.00%-50.00%-60.53%-57.14%-87.78%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-3.76%-18.21%-36.95%-71.17%-90.05%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-3.81%+14.97%+10.02%-30.80%-44.31%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
1.00
SellN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
2.00
Hold$13.00915.63% Upside
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest BPTH, CVKD, RDHL, and ADXN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/3/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/6/2026
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
$210K21.73N/AN/A$4.67 per share0.79
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/A$1.15 per shareN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$290K14.94N/AN/A$0.83 per share0.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
-$8.12M-$5.94N/AN/AN/AN/A-134.76%-106.00%11/9/2026 (Estimated)
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08M-$1.09N/AN/AN/AN/A-2,842.40%-337.48%11/12/2026 (Estimated)
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$13.24M-$4.90N/AN/AN/AN/A-406.41%-273.80%11/9/2026 (Estimated)
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$430K$900.000.00N/AN/AN/AN/AN/AN/A

Latest BPTH, CVKD, RDHL, and ADXN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.42-$1.14+$0.28-$1.14N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
N/AN/AN/AN/AN/A
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
N/A
0.97
0.97
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/A
3.73
3.73
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.34
0.34

Institutional Ownership

CompanyInstitutional Ownership
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
16.14%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
7.92%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%

Insider Ownership

CompanyInsider Ownership
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
15.00%
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
14.59%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd. Sponsored ADR stock logo
ADXN
Addex Therapeutics
301.23 million1.05 millionNot Optionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
1053.90 million5.73 millionNo Data
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
43.57 million3.05 millionNot Optionable
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2106.08 million5.67 millionNo Data

Recent News About These Companies

RedHill acquires rights to Ferring’s Rebyota and Clenpiq
September 1 at 3:35 PM  |  thepharmaletter.comT
Redhill Biopharma stock doubles in one session — here's why
September 1 at 3:35 PM  |  msn.comhttps://www.msn.com/en-us/news/other/redhill-biopharma-stock-doubles-in-one-session-here-s-why/ar-AA2bhfIt
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
September 1 at 10:31 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferring-s-rebyota-and-clenpiq-1036510879
RedHill divests Talicia business to Apotex
September 1 at 10:31 AM  |  thepharmaletter.comT
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
September 1 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferrings-rebyota-and-clenpiq-302866106.html
RedHill Biopharma Stock Surges 64% Over Deal To Divest Talicia Business
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3687115/redhill-biopharma-stock-surges-64-over-deal-to-divest-talicia-business.aspx
RedHill Biopharma (NASDAQ: RDHL) Soars to $1.60 - Monetizes Talicia Stake in $18 Million Cash Deal With Apotex
August 31, 2026  |  investorideas.comI
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-divests-talicia-to-apotex-for-18-million-cash-upfront-plus-milestones-to-fuel-strategic-growth-opportunities-302864832.html
Redhill Biopharma Ltd (NASDAQ: RDHL) - Share Price and Research
August 8, 2026  |  intelligentinvestor.com.auI
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
July 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ebola-cases-and-deaths-rapidly-mount---redhill-updates-on-opaganib-emergency-outbreak-development-302836392.html
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
June 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html
RedHill Biopharma announces up to $19.4M private placement
June 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/redhill-biopharma-announces-up-to-194m-private-placement/ar-AA25Xq2A
RedHill Biopharma Announces Up To $19.4 Million Private Placement
June 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html
RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak
June 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RDHL/pressreleases/2280827/redhill-biopharma-moves-to-advance-opaganib-as-oral-antiviral-option-for-current-ebola-outbreak/
RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
June 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68718281-redhill-biopharma-ltd-redhill-s-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan-drug-design-008.htm
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
June 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhills-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan-drug-designation-302795146.html
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-launches-enforcement-of-11-million-new-york-supreme-court-final-judgment-against-kukbo-302793864.html
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
June 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-advancing-opaganib-options-for-novel-dual-host-directed-and-direct-acting-antiviral-approach-for-ebola-outbreak-biodefense-platforms-302788468.html
Bessor Announces Entering Option for the Redhill Property
May 26, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/26/3301289/0/en/bessor-announces-entering-option-for-the-redhill-property.html
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
April 30, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhills-rhb-204-demonstrates-comparable-map-killing-efficacy-to-rhb-104---important-step-in-rhb-204-development-for-map-related-crohns-disease-302758691.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics NASDAQ:ADXN

$3.71 +0.19 (+5.40%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$3.78 +0.08 (+2.02%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.02 -0.01 (-25.00%)
As of 09/3/2026 03:57 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

Cadrenal Therapeutics stock logo

Cadrenal Therapeutics NASDAQ:CVKD

$1.28 -0.05 (-3.76%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$1.30 +0.02 (+1.48%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$0.71 -0.03 (-3.81%)
Closing price 09/3/2026 04:00 PM Eastern
Extended Trading
$0.70 -0.01 (-1.52%)
As of 08:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas